Facial Injectables are the face skin fillers that are used in many applications like dark circles removal, uplifting of eyebrows, thinning of the lips, enhancement of cheekbones and others applications.Facial injectable are also used to reduce wrinkles and smoothen skin appearance caused by ageing, acne or scars. The major application areas are face including nasolabial fold, cheeks, lips, corners of the eye and for enhancing appearance of dorsal area of hands. There are two major types of facial Injectable namely botulinum toxin and dermal fillers. Some of the key commercially available botulinum toxin brands include Dysport, Xeomin, Meditoxin, Botulax and Nabota. Dermal fillers may be of Hyaluronic acid based, Calcium Hydroxyapatite based, Poly-Lactic acid based, collagen based or Polymethylmethacrylate-based (non-absorbable).

Fig 1: CEE FACIAL INJECTABLES MARKET, BY SEGMENTATION

The key factors for the growth of the facial injectables market in CEE region include the rising aesthetic consciousness and number of cosmetic procedures, the introduction of cost-effective facial injectable, and the aging population. As the cosmetic industry is booming, there has been an increase in the total number of non-surgical therapies, such as injections of wrinkle relaxers and dermal fillers. This trend is primarily due to the advantages of technologies, such as low recovery time, less risk of infections, no blood loss, and the overall reduction in procedural costs. Thus, the increase in the number of cosmetic procedures has spurred the growth of the overall market. In addition, there is a consistent rise in the geriatric population that helps to boost the market growth. Along with the aging population, the new generation has been attracted to the cosmetic industry to appear more youthful. Furthermore, technological advancements are also helping in the growth of the market. However, strict regulatory concerns of injectable products and side effects of such products such as rashes restrict market growth.

The CEE facial injectables market is segmented into two major market segments, namely; by product and by end user.

Fig 2: CEE FACIAL INJECTABLES MARKET, BY PRODUCT

The product segment includes dermal fillers/injectable implants, and anti-aging/ anti-wrinkle injections. The dermal fillers segment is expacted to dominate the CEE facial injectables market in 2020. Dermal fillers segment is further categorized into hyaluronic acid fillers, collagen fillers and synthetic fillers while anti-ageing injections are divided into botulinum toxin A and poly-L-lactic acid (PLLA) micro particles. The hyaluronic acid segment dominated the market in 2019 and is expected to witness lucrative growth over the forecast period. Increasing application of hyaluronic acid in cosmetic industry is expected to support the growth. Hyaluronic acid was first used in medicine in mid 1980s. Currently, HA is the world’s most frequently used filler. It is among the natural chemical substances found in the skin and serves as a major structural component of extracellular space. When used in aesthetic medicine, hyaluronic acid is cross-linked which means it is subjected to a process aimed at prolonging its residence time in tissue. Hyaluronic acid obtained by bio-technology is characterized by a high purity and very good biocompatability. The European Commission considers fillers to be medical devices, and it is easier to obtain a CE mark than FDA (Food and Drug Administration) approval. Many of the Central and Eastern European countries have high-cohesivity HAs, as well as very low-cohesivity HAs, that are not available in the United States.

Fig 3: CEE FACIAL INJECTABLES MARKET, BY END USER

The end user segment includes hospitals, dermatology clinics, beauty clinics, and dermatology research institute. The hospitals segment is expected to hold the largest market share in 2020 as the number of hospitals and the flow of patients in hospital establishment is increasing at an exponential rate. With growing population across the nations, the demand for hospitals and relaiable healthcare in rapidly increasing. Growing number of hospitals and increasing inflow of patients in the hospital establishments is the primary factor driving the growth of facial injectables market in hospitals in the CEE region. In 2017, there were 1,058 hospitals in Poland. The number of hospitals in Poland has generally increased since the year 2000, when there were approximately 800 hospitals in the country. Also, in Bulgaria there were 322 hospitals in 2018, compared to the 312 that were recorded in 2010. Many of these hospitals have a separate aesthetic department that focuses on treatments for the face, maintain skin and add volume and shape to the skin, thus drives the demand for facial injectable products. However, dermatology clinics segment is expected to witness fastest growth during the forecast period.

Fig 4: CEE FACIAL INJECTABLES MARKET, BY COUNTRY

On the basis of the country the CEE facial injectable market is segmented into Poland, CZECH Republic, Croatia, Bulgaria, Romania, Hungary, Slovakia, Estonia, Latvia, Slovenia, and Lithuania. In 2020, Poland is expected to dominate the CEE facial injectable market and is also expected to maintain its dominance during the forecast period. Factors such as increasing healthcare expenditure, growing investments in the dermatological and cosmetic surgery field, increasing adoption of plastic surgery and growing skin care techniques are driving the growth of the market in Poland. Furthermore, growing government investments in development of healthcare infrastructure and increasing implementation o advanced technologies are also fueling the growth of this regional segment.

Fig 5: CEE FACIAL INJECTABLE MARKET SEGMENT OUTLOOK

Companies Covered: Allergan Plc, Merz Inc, Galderma Laboratories, Colbar Lifescience Ltd, Sanofi Biosurgery Inc, Anika Therapeutics, Inc, Prollelium Medical Technologies Inc, Suneva Medical Inc, Zimmer Biomet, Sinclair Pharma, Sculpt Luxury Dermal Fillers Ltd, Bioxis Pharmaceuticals, Scivision Biotech Inc.

Market Segments

By Product

• Dermal Fillers/Injectable Implants
  • Hyaluronic Acid Fillers
  • Collagen Fillers
  • Synthetic Fillers
• Anti-Aging/ Anti-Wrinkle Injections
  • Botulinum Toxin A
  • Poly-L-Lactic Acid (PLLA) Micro Particles

By End User

• Hospitals
• Dermatology Clinics
• Beauty Clinics
• Dermatology Research Institutes

Country Analysis CEE Facial Injectables Market

• Poland
• Czech Republic
• Bulgaria
• Croatia
• Slovakia
• Romania
• Estonia
• Latvia
• Hungary
• Slovenia
• Lithuania

Reasons To Buy This Report:

• Market size estimation of the CEE facial injectable market on a regional and global basis
• The unique research design for market size estimation and forecast
• Profiling of major companies operating in the market with key developments
• Broad scope to cover all the possible segments helping every stakeholder in the market

Customization:

We provide customization of the study to meet specific requirements:

• By Segment
• By Sub-segment
• By Region/Country

For more information, contact: [email protected]           

Table Of Contents

1              Market Abstract

2              Market Introduction

2.1          Market Scope

3              QMI Research Practice

3.1          Research Practice

3.1.1      Supply Based Analysis

3.1.2      Demand Based Analysis

3.1.3      Global Level Analysis

3.1.4      Country Level Analysis

3.1.5      Triangulation

3.2          Primary Data

3.3          Secondary Data

3.4          Market Evaluation & Forecasting Methodology

3.5          Assumptions/ Limitations For The Study

3.6          What This Study Provides

3.7          Key Questions Answered By This Report

3.8          This Study Is Intended For

4              Key Related Data

4.1          Competitive Positioning

4.1.1      Product Positioning

4.1.2      Revenue Positioning

4.1.3      Regional Reach Positioning

4.2          Cee Healthcare Sector Data

4.3          Major Investments In Last Five Years By Global Players

4.4          Guidelines & Regulations

4.5          Key Industry Trends

4.6          Technological Advancement In Filler And Injectable Devices In  Cee Region

5              Impact Factor Analysis

5.1          Micro Economic Pointers

5.1.1      Research And Development Investment By Company

5.2          Macro Economic Pointers

5.2.1      Number Of Hospitals, By Country

5.2.2      Population, By Country

5.3          Porter’s Five Forces Model

6              Market Development Analysis

6.1          Overview

6.2          New Product Development, Launch And Approval (2016-2020)

6.3          Agreement, Partnership & Collaboration (2016-2020)

6.4          Merger & Acquisitions (2016-2020)

6.5          Expansions (2016-2020)

6.6          Others (2016-2020)

7              CEE Facial Injectable Market, By Product

7.1          Introduction

7.2          Dermal Fillers/Injectable Implants

7.2.1      Hyaluronic Acid Fillers

7.2.2      Collagen Fillers

7.2.3      Synthetic Fillers

7.3          Anti-Aging/ Anti-Wrinkle Injections

7.3.1      Botulinum Toxin A

7.3.2      Poly-L-Lactic Acid (Plla) Micro Particles

8              CEE Facial Injectable Market, By End User

8.1          Introduction

8.2          Hospitals

8.3          Dermatology Clinics

8.4          Beauty Clinics

8.5          Dermatology Research Institutes

9              CEE Facial Injectable Market, Country Analysis

9.1          Introduction

9.2          Poland

9.3          Czech Republic

9.4          Bulgaria

9.5          Croatia

9.6          Slovakia

9.7          Romania

9.8          Estonia

9.9          Latvia

9.10        Hungary

9.11        Slovenia

9.12        Lithuania

10           Company Profile

10.1        Allergan Plc

10.1.1    Company Overview

10.1.2    Allergan Plc: Financial Overview

10.1.3    Allergan Plc: Product Overview

10.1.4    Allergan Plc: Swot Analysis

10.1.5    Allergan Plc: Key Developments (2017-2020)

10.2        Merz Inc.

10.2.1    Company Overview

10.2.2    Merz Inc.: Financial Overview

10.2.3    Merz Inc.: Product Overview

10.2.4    Merz Inc.: Swot Analysis

10.2.5    Merz Inc.: Key Developments (2016-2020)

10.3        Galderma Laboratories

10.3.1    Company Overview

10.3.2    Galderma Laboratories: Product Overview

10.3.3    Galderma Laboratories: Swot Analysis

10.3.4    Galderma Laboratories: Key Developments (2017-2020)

10.4        Colbar Lifescience Ltd.

10.4.1    Company Overview       

10.4.2    Colbar Lifescience Ltd: Product Overview

10.4.3    Colbar Lifescience Ltd: Key Developments (2017-2020)

10.5        Sanofi Biosurgery Inc.   

10.5.1    Company Overview       

10.5.2    Financial Overview         

10.5.3    Sanofi Biosurgery Inc.: Product Overview

10.5.4    Sanofi: Swot Analysis

10.5.5    Sanofi Biosurgery Inc.: Key Developments (2017-2020)

10.6        Anika Therapeutics, Inc.

10.6.1    Company Overview       

10.6.2    Financial Overview         

10.6.3    Anika Therapeutics: Product Overview

10.6.4    Anika Therapeutics: Swot Analysis          

10.6.5    Anika Therapeutics: Key Developments (2017-2020)

10.7        Teoxane Laboratories   

10.7.1    Company Overview       

10.7.2    Teoxane Laboratories: Product Overview

10.7.3    Teoxane Laboratories: Swot Analysis     

10.7.4    Teoxane Laboratories: Key Developments (2017-2020)

10.8        Prollelium Medical Technologies Inc.

10.8.1    Company Overview       

10.8.2    Prollelium Medical Technologies Inc.: Product Overview

10.8.3    Prollelium Medical Technologies Inc.: Swot Analysis

10.8.4    Prollelium Medical Technologies Inc.: Key Developments (2017-2020)

10.9        Suneva Medical Inc.

10.9.1    Company Overview       

10.9.2    Suneva Medical Inc.: Product Overview

10.9.3    Suneva Medical Inc.: Swot Analysis

10.9.4    Suneva Medical Inc.: Key Developments (2017-2020)

10.10     Zimmer Biomet

10.10.1  Company Overview

10.10.2  Financial Overview         

10.10.3  Zimmer Biomet: Product Overview         

10.10.4  Zimmer Biomet: Swot Analysis

10.10.5  Zimmer Biomet: Key Developments (2017-2020)

10.11     Sinclair Pharma

10.11.1  Company Overview

10.11.2  Sinclair Pharma: Product Overview

10.11.3  Sinclair Pharma: Swot Analysis

10.11.4  Sinclair Pharma: Key Developments (2017-2020)

10.12     Sculpt Luxury Dermal Fillers Ltd

10.12.1  Company Overview

10.12.2  Sculpt Luxury Dermal Fillers Ltd: Product Overview

10.12.3  Sculpt Luxury Dermal Fillers Ltd: Key Developments (2017-2020)

10.13     Bioxis Pharmaceuticals

10.13.1  Company Overview

10.13.2  Bioxis Pharmaceuticals: Product Overview

10.13.3  Bioxis Pharmaceuticals: Key Developments (2017-2020)

10.14     Scivision Biotech Inc

10.14.1  Company Overview

10.14.2  Financial Overview

10.14.3  Scivision Biotech Inc: Product Overview

10.14.4  Scivision Biotech Inc: Key Developments (2017-2020)

11           Appendix           

11.1        List Of Abbreviation

11.2        Key Related Reports

 

LIST OF TABLES

TABLE 1                NEW PRODUCT DEVELOPMENT, LAUNCH AND APPROVAL (2016-2020)

TABLE 2                AGREEMENT, PARTNERSHIP & COLLABORATION (2016-2020)

TABLE 3                MERGER & ACQUISITIONS (2016-2020)

TABLE 4                EXPANSIONS (2016-2020)

TABLE 5                OTHERS (2016-2020)

TABLE 6                CEE FACIAL INJECTABLE MARKET, BY PRODUCT (USD MILLION)

TABLE 7                CEE DERMAL FILLERS/INJECTABLE IMPLANTS MARKET, BY TYPE (USD MILLION)

TABLE 8                CEE DERMAL FILLERS/INJECTABLE IMPLANTS MARKET, BY COUNTRY (USD MILLION)

TABLE 9                HYALURONIC ACID FILLERS MARKET – BY COUNTRY (USD MILLION)

TABLE 10        COLLAGEN FILLERS MARKET, BY COUNTRY (USD MILLION)

TABLE 11              SYNTHETIC FILLERS MARKET, BY COUNTRY (USD MILLION)

TABLE 12              ANTI-AGING/ ANTI-WRINKLE INJECTIONS MARKET, BY TYPE (USD MILLION)

TABLE 13              ANTI-AGING/ ANTI-WRINKLE INJECTIONS MARKET, BY COUNTRY (USD MILLION)

TABLE 14              BOTULINUM TOXIN A MARKET – BY COUNTRY (USD MILLION)

TABLE 15              POLY-L-LACTIC ACID (PLLA) MICRO PARTICLES MARKET, BY COUNTRY (USD MILLION)

TABLE 16              CEE FACIAL INJECTABLE MARKET, BY END USER (USD MILLION)

TABLE 17              FACIAL INJECTABLE MARKET IN HOSPITALS, BY COUNTRY (USD MILLION)

TABLE 18              FACIAL INJECTABLE MARKET IN DERMATOLOGY CLINICS – BY COUNTRY (USD MILLION)

TABLE 19              FACIAL INJECTABLE MARKET FOR BEAUTY CLINICS, BY COUNTRY (USD MILLION)

TABLE 20              FACIAL INJECTABLE MARKET FOR DERMATOLOGY RESEARCH INSTITUTES, BY COUNTRY (USD MILLION)

TABLE 21              CEE FACIAL INJECTABLE MARKET, BY COUNTRY (USD MILLION)

TABLE 22              POLAND FACIAL INJECTABLE MARKET, BY PRODUCT (USD MILLION)

TABLE 23              POLAND DERMAL FILLERS/ INJECTABLE IMPLANTS MARKET, BY TYPE (USD MILLION)

TABLE 24              POLAND ANTI-AGING/ ANTI-WRINKLE INJECTIONS MARKET, BY TYPE (USD MILLION)

TABLE 25              POLAND FACIAL INJECTABLE MARKET, BY END USER (USD MILLION)

TABLE 26              CZECH REPUBLIC FACIAL INJECTABLE MARKET, BY PRODUCT (USD MILLION)

TABLE 27              CZECH REPUBLIC DERMAL FILLERS/ INJECTABLE IMPLANTS MARKET,  BY TYPE (USD MILLION)

TABLE 28              CZECH REPUBLIC ANTI-AGING/ ANTI-WRINKLE INJECTIONS MARKET, BY TYPE (USD MILLION)

TABLE 29              CZECH REPUBLIC FACIAL INJECTABLE MARKET, BY END USER (USD MILLION)

TABLE 30              BULGARIA FACIAL INJECTABLE MARKET, BY PRODUCT (USD MILLION)

TABLE 31              BULGARIA DERMAL FILLERS/ INJECTABLE IMPLANTS MARKET, BY TYPE (USD MILLION)

TABLE 32              BULGARIA ANTI-AGING/ ANTI-WRINKLE INJECTIONS MARKET, BY TYPE (USD MILLION)

TABLE 33              BULGARIA FACIAL INJECTABLE MARKET, BY END USER (USD MILLION)

TABLE 34              CROATIA FACIAL INJECTABLE MARKET, BY PRODUCT (USD MILLION)

TABLE 35              CROATIA DERMAL FILLERS/ INJECTABLE IMPLANTS MARKET, BY TYPE (USD MILLION)

TABLE 36              CROATIA ANTI-AGING/ ANTI-WRINKLE INJECTIONS MARKET, BY TYPE (USD MILLION)

TABLE 37              CROATIA FACIAL INJECTABLE MARKET, BY END USER (USD MILLION)

TABLE 38              SLOVAKIA FACIAL INJECTABLE MARKET, BY PRODUCT (USD MILLION)

TABLE 39              SLOVAKIA DERMAL FILLERS/ INJECTABLE IMPLANTS MARKET, BY TYPE (USD MILLION)

TABLE 40              SLOVAKIA ANTI-AGING/ ANTI-WRINKLE INJECTIONS MARKET, BY TYPE (USD MILLION)

TABLE 41              SLOVAKIA FACIAL INJECTABLE MARKET, BY END USER (USD MILLION)

TABLE 42              ROMANIA FACIAL INJECTABLE MARKET, BY PRODUCT (USD MILLION)

TABLE 43              ROMANIA DERMAL FILLERS/ INJECTABLE IMPLANTS MARKET, BY TYPE (USD MILLION)

TABLE 44              ROMANIA ANTI-AGING/ ANTI-WRINKLE INJECTIONS MARKET, BY TYPE (USD MILLION)

TABLE 45              ROMANIA FACIAL INJECTABLE MARKET, BY END USER (USD MILLION)

TABLE 46              ESTONIA FACIAL INJECTABLE MARKET, BY PRODUCT (USD MILLION)

TABLE 47              ESTONIA DERMAL FILLERS/ INJECTABLE IMPLANTS MARKET, BY TYPE (USD MILLION)

TABLE 48              ESTONIA ANTI-AGING/ ANTI-WRINKLE INJECTIONS MARKET, BY TYPE (USD MILLION)

TABLE 49              ESTONIA FACIAL INJECTABLE MARKET, BY END USER (USD MILLION)

TABLE 50              LATVIA FACIAL INJECTABLE MARKET, BY PRODUCT (USD MILLION)

TABLE 51              LATVIA DERMAL FILLERS/ INJECTABLE IMPLANTS MARKET, BY TYPE (USD MILLION)

TABLE 52              LATVIA ANTI-AGING/ ANTI-WRINKLE INJECTIONS MARKET, BY TYPE (USD MILLION)

TABLE 53              LATVIA FACIAL INJECTABLE MARKET, BY END USER (USD MILLION)

TABLE 54              HUNGARY FACIAL INJECTABLE MARKET, BY PRODUCT (USD MILLION)

TABLE 55              HUNGARY DERMAL FILLERS/ INJECTABLE IMPLANTS MARKET, BY TYPE (USD MILLION)

TABLE 56              HUNGARY ANTI-AGING/ ANTI-WRINKLE INJECTIONS MARKET, BY TYPE (USD MILLION)

TABLE 57              HUNGARY FACIAL INJECTABLE MARKET, BY END USER (USD MILLION)

TABLE 58              SLOVENIA FACIAL INJECTABLE MARKET, BY PRODUCT (USD MILLION)

TABLE 59              SLOVENIA DERMAL FILLERS/ INJECTABLE IMPLANTS MARKET, BY TYPE (USD MILLION)

TABLE 60              SLOVENIA ANTI-AGING/ ANTI-WRINKLE INJECTIONS MARKET, BY TYPE (USD MILLION)

TABLE 61              SLOVENIA FACIAL INJECTABLE MARKET, BY END USER (USD MILLION)

TABLE 62              LITHUANIA FACIAL INJECTABLE MARKET, BY PRODUCT (USD MILLION)

TABLE 63              LITHUANIA DERMAL FILLERS/ INJECTABLE IMPLANTS MARKET, BY TYPE (USD MILLION)

TABLE 64              LITHUANIA ANTI-AGING/ ANTI-WRINKLE INJECTIONS MARKET, BY TYPE (USD MILLION)

TABLE 65              LITHUANIA FACIAL INJECTABLE MARKET, BY END USER (USD MILLION)

 

LIST OF FIGURES

FIGURE 1             CEE FACIAL INJECTABLES MARKET, BY PRODUCT

FIGURE 2             CEE FACIAL INJECTABLES MARKET, BY END USER

FIGURE 3             CEE FACIAL INJECTABLES MARKET, BY COUNTRY

FIGURE 4             CEE FACIAL INJECTABLE MARKET – MARKET SCOPE

FIGURE 5             CEE FACIAL INJECTABLE MARKET –RESEARCH PRACTICE

FIGURE 6             CEE FACIAL INJECTABLE MARKET –RESEARCH METHODOLOGY

FIGURE 7             CEE FACIAL INJECTABLE MARKET –PRIMARY AND SECONDARY RESEARCH

FIGURE 8             CEE: HEALTHCARE SPENDING AS PERCENTAGE OF GDP

FIGURE 9             CEE AND NEARBY EMERGING MARKETS ATTRACTING MOST PRIVATE INVESTMENT IN HEALTHCARE

FIGURE 10           PORTER’S FIVE FORCES MODEL- CEE FACIAL INJECTABLE MARKET

FIGURE 11           CEE FACIAL INJECTABLE MARKET – MARKET DEVELOPMENT ANALYSIS (ORGANIC VS INORGANIC)

FIGURE 12           NEW PRODUCT DEVELOPMENT, LAUNCH AND APPROVAL IS THE MOST PREFFERED STRATEGY ADOPTED BY THE KEY PLAYERS BETWEEN 2016 AND 2020

FIGURE 13           CEE FACIAL INJECTABLE MARKET – BY PRODUCT

FIGURE 14           CEE DERMAL FILLERS/INJECTABLE IMPLANTS MARKET – BY TYPE

FIGURE 15           CEE HYALURONIC ACID FILLERS MARKET – BY COUNTRY

FIGURE 16           COLLAGEN FILLERS MARKET – BY COUNTRY

FIGURE 17           SYNTHETIC FILLERS MARKET – BY COUNTRY

FIGURE 18           ANTI-AGING/ ANTI-WRINKLE INJECTIONS MARKET – BY TYPE

FIGURE 19           BOTULINUM TOXIN A MARKET – BY COUNTRY

FIGURE 20           POLY-L-LACTIC ACID (PLLA) MICRO PARTICLES MARKET – BY COUNTRY

FIGURE 21           CEE FACIAL INJECTABLE MARKET – BY END USER

FIGURE 22           FACIAL INJECTABLE MARKET IN HOSPITALS – BY COUNTRY

FIGURE 23           FACIAL INJECTABLE MARKET IN DERMATOLOGY CLINICS – BY COUNTRY

FIGURE 24           FACIAL INJECTABLE MARKET IN BEAUTY CLINICS – BY COUNTRY

FIGURE 25           FACIAL INJECTABLE MARKET IN DERMATOLOGY RESEARCH INSTITUTES – BY COUNTRY

FIGURE 26           CEE FACIAL INJECTABLE MARKET - OVERVIEW

FIGURE 27           CEE FACIAL INJECTABLE MARKET – BY COUNTRY

FIGURE 28           POLAND FACIAL INJECTABLE MARKET, OVERVIEW 2020

FIGURE 29           CZECH REPUBLIC FACIAL INJECTABLE MARKET, OVERVIEW 2020

FIGURE 30           BULGARIA FACIAL INJECTABLE MARKET, OVERVIEW 2020

FIGURE 31           CROATIA FACIAL INJECTABLE MARKET, OVERVIEW 2020

FIGURE 32           SLOVAKIA FACIAL INJECTABLE MARKET,OVERVIEW 2020

FIGURE 33           ROMANIA FACIAL INJECTABLE MARKET, OVERVIEW 2020

FIGURE 34           ESTONIA FACIAL INJECTABLE MARKET, OVERVIEW, 2020

FIGURE 35           LATVIA FACIAL INJECTABLE MARKET, OVERVIEW 2020

FIGURE 36           HUNGARY FACIAL INJECTABLE MARKET, OVERVIEW 2020

FIGURE 37           SLOVENIA FACIAL INJECTABLE MARKET, OVERVIEW 2020

FIGURE 38           LITHUANIA FACIAL INJECTABLE MARKET, OVERVIEW 2020

FIGURE 39           ALLERGAN PLC: (COMPANY OVERVIEW)

FIGURE 40           ALLERGAN PLC (FINANCIAL OVERVIEW)

FIGURE 41           ALLERGAN PLC: SWOT ANALYSIS

FIGURE 42           MERZ INC.: (COMPANY OVERVIEW)

FIGURE 43           MERZ INC. (FINANCIAL OVERVIEW)

FIGURE 44           MERZ INC. (SWOT ANALYSIS)

FIGURE 45           GALDERMA LABORATORIES: (COMPANY OVERVIEW)

FIGURE 46           GALDERMA LABORATORIES (SWOT ANALYSIS)

FIGURE 47           COLBAR LIFESCIENCE LTD: (COMPANY OVERVIEW)

FIGURE 48           SANOFI: (COMPANY OVERVIEW)

FIGURE 49           SANOFI: (FINANCIAL OVERVIEW)

FIGURE 50           SANOFI: (SWOT ANALYSIS)

FIGURE 51           ANIKA THERAPEUTICS: (COMPANY OVERVIEW)

FIGURE 52           ANIKA THERAPEUTICS: (FINANCIAL OVERVIEW)

FIGURE 53           ANIKA THERAPEUTICS: (SWOT ANALYSIS)

FIGURE 54           TEOXANE LABORATORIES: (COMPANY OVERVIEW)

FIGURE 55           TEOXANE LABORATORIES: (SWOT ANALYSIS)

FIGURE 56           PROLLELIUM MEDICAL TECHNOLOGIES INC.: (COMPANY OVERVIEW)

FIGURE 57           PROLLELIUM MEDICAL TECHNOLOGIES INC.: (SWOT ANALYSIS)

FIGURE 58           SUNEVA MEDICAL INC.: (COMPANY OVERVIEW)

FIGURE 59           SUNEVA MEDICAL INC.: (SWOT ANALYSIS)

FIGURE 60           ZIMMER BIOMET: (COMPANY OVERVIEW)

FIGURE 61           ZIMMER BIOMET: (FINANCIAL OVERVIEW)

FIGURE 62           ZIMMER BIOMET: (SWOT ANALYSIS)

FIGURE 63           SINCLAIR PHARMA: (COMPANY OVERVIEW)

FIGURE 64           SINCLAIR PHARMA: (SWOT ANALYSIS)

FIGURE 65           SCULPT LUXURY DERMAL FILLERS LTD: (COMPANY OVERVIEW)

FIGURE 66           BIOXIS PHARMACEUTICALS: (COMPANY OVERVIEW)

FIGURE 67           SCIVISION BIOTECH INC: (COMPANY OVERVIEW)

FIGURE 68           SCIVISION BIOTECH INC: (COMPANY OVERVIEW)